Skip to main content
Arvee Laboratories (India) Limited logo

Arvee Laboratories (India) Limited — Investor Relations & Filings

Ticker · ARVEE ISIN · INE006Z01016 LEI · 33580075Q2EAWYCO4C50 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2024-04-22 Regulatory Filings
Country IN India
Listing National Stock Exchange of India ARVEE

About Arvee Laboratories (India) Limited

http://arveelabs.com/

Arvee Laboratories (India) Limited specializes in the manufacturing and export of specialty chemicals and pharmaceutical intermediates. The company focuses on the production of high-quality chemical compounds, including Dimethyl 5-Sulfoisophthalate Sodium Salt (DMSIP), 5-Sulfoisophthalic Acid Monosodium Salt, and various other aromatic intermediates. These products serve as critical components in the textile, polymer, and pharmaceutical sectors. Arvee Laboratories emphasizes research and development to enhance its chemical synthesis processes and maintain international quality standards. Its operations involve complex chemical reactions such as sulfonation, esterification, and reduction, catering to a diverse global clientele requiring specialized chemical solutions for industrial applications.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-04-22 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited providing a clarification on the movement in the company's share price. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and states there are no material events requiring disclosure. The document is short (1545 characters) and serves as a regulatory communication rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance communications.
2024-04-08 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to the National Stock Exchange of India Limited regarding the reconstitution of various board committees such as the Audit Committee, Stakeholders Committee, Corporate Social Responsibility Committee, and Nomination and Remuneration Committee. It lists the members and chairpersons of these committees and states the effective date of these changes. There is no financial data, no report attached or referenced as published, and no mention of voting results or other report types. The content clearly relates to changes in the company's board or committee structure, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on committee reconstitution, confirming it is not an annual report or other financial filing.
2024-04-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notification from Arvee Laboratories (India) Limited addressed to the National Stock Exchange of India. It informs about the closure of the trading window for insiders ahead of the quarterly results announcement for the quarter ended March 31, 2024. The content is a compliance announcement related to insider trading regulations and trading restrictions, not a financial report or detailed disclosure of results. The document length is short (1439 characters) and it does not contain financial data or detailed report content. It is an announcement related to trading restrictions rather than a report or filing of financial results or management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-27 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal notification to the stock exchange about the resignation of an independent director, Mr. Dipen Dalal, from Arvee Laboratories (India) Limited. It references compliance with SEBI Listing Regulations and provides details about the resignation, including the date of cessation and reasons. There is no financial data, report, or presentation included. This fits the category of announcements related to changes in the company's board of directors or senior management.
2024-03-26 English
Financial Result Updates
Regulatory Filings
2024-02-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.